Evidence map›Paper›PMID 37454128›Full record

ArticleAnnals of clinical microbiology and antimicrobials2023

High prevalence of colistin heteroresistance in specific species and lineages of Enterobacter cloacae complex derived from human clinical specimens.

Shota Fukuzawa, Toyotaka Sato, Kotaro Aoki, Soh Yamamoto, Noriko Ogasawara, Chie Nakajima, Yasuhiko Suzuki, Motohiro Horiuchi, Satoshi Takahashi, Shin-Ichi Yokota

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 19 citations in OpenAlex.

  1. Dual resistance to carbapenems and colistin inEmerging microbes & infections · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Colistin heteroresistance inAntimicrobial agents and chemotherapy · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Use of CHROMIDAntibiotics (Basel, Switzerland) · 2024
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Shota FukuzawaDepartment of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Toyotaka SatoDepartment of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan. sato.t@vetmed.hokudai.ac.jp.
Kotaro AokiDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
Soh YamamotoDepartment of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Noriko OgasawaraDepartment of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Chie NakajimaDivision of Bioresources, Hokkaido University International Institute for Zoonosis Control, Sapporo, Japan.
Yasuhiko SuzukiDivision of Bioresources, Hokkaido University International Institute for Zoonosis Control, Sapporo, Japan.
Motohiro HoriuchiLaboratory of Veterinary Hygiene, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Satoshi TakahashiDepartment of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Shin-Ichi YokotaDepartment of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Sapporo Medical University · JPHokkaido University · JPNational Hospital Organization Hokkaido Medical Center · JPSapporo International University · JPSapporo University · JPToho University · JP

Funding

Japan Agency for Medical Research and Development JP20ak0101118h0002Japan Agency for Medical Research and Development JP223fa627005Japan Science and Technology Agency ST211004JOJSPS KAKENHI JP21H03622
6 · The paper itself

Abstract

backgroundColistin (CST) is a last-line drug for multidrug-resistant Gram-negative bacterial infections. CST-heteroresistant Enterobacter cloacae complex (ECC) has been isolated. However, integrated analysis of epidemiology and resistance mechanisms based on the complete ECC species identification has not been performed.

methodsClinical isolates identified as "E. cloacae complex" by MALDI-TOF MS Biotyper Compass in a university hospital in Japan were analyzed. Minimum inhibitory concentrations of CST were determined by the broth microdilution method. The population analysis profiling (PAP) was performed for detecting the heteroresistant phenotype. The heat shock protein 60 (hsp60) cluster was determined from its partial nucleotide sequence. From the data of whole-genome sequencing, average nucleotide identity (ANI) for determining ECC species, multilocus sequence type, core genome single-nucleotide-polymorphism-based phylogenetic analysis were performed. phoPQ-, eptA-, and arnT-deleted mutants were established to evaluate the mechanism underlying colistin heteroresistance. The arnT mRNA expression levels were determined by reverse transcription quantitative PCR.

resultsThirty-eight CST-resistant isolates, all of which exhibited the heteroresistant phenotype by PAP, were found from 138 ECC clinical isolates (27.5%). The prevalence of CST-resistant isolates did not significantly differ among the origin of specimens (29.0%, 27.8%, and 20.2% for respiratory, urine, and blood specimens, respectively). hsp60 clusters, core genome phylogeny, and ANI revealed that the CST-heteroresistant isolates were found in all or most of Enterobacter roggenkampii (hsp60 cluster IV), Enterobacter kobei (cluster II), Enterobacter chuandaensis (clusters III and IX), and Enterobacter cloacae subspecies (clusters XI and XII). No heteroresistant isolates were found in Enterobacter hormaechei subspecies (clusters VIII, VI, and III) and Enterobacter ludwigii (cluster V). CST-induced mRNA upregulation of arnT, which encodes 4-amino-4-deoxy-L-arabinose transferase, was observed in the CST-heteroresistant isolates, and it is mediated by phoPQ pathway. Isolates possessing mcr-9 and mcr-10 (3.6% and 5.6% of total ECC isolates, respectively) exhibited similar CST susceptibility and PAP compared with mcr-negative isolates.

conclusionsSignificant prevalence (approximately 28%) of CST heteroresistance is observed in ECC clinical isolates, and they are accumulated in specific species and lineages. Heteroresistance is occurred by upregulation of arnT mRNA induced by CST. Acquisition of mcr genes contributes less to CST resistance in ECC.

Indexed as

ColistinEnterobacteriaceae InfectionsAnti-Bacterial AgentsEnterobacter cloacaeHumansMicrobial Sensitivity TestsNucleotidesPhylogenyPrevalenceAnti-Bacterial AgentsColistinNucleotidesarnTAverage nucleotide identity (ANI)ColistinEnterobacter cloacae complexHeteroresistancePhoPQ

Identifiers

PMID37454128
PMCPMC10350281
OpenAlexW4384405490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.